Jasper Therapeutics (NASDAQ:JSPR) Upgraded to Strong-Buy at Piper Sandler

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by investment analysts at Piper Sandler to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

JSPR has been the subject of several other research reports. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. TD Cowen downgraded shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.57.

Jasper Therapeutics Stock Down 7.7%

Shares of NASDAQ JSPR opened at $0.82 on Wednesday. The firm’s 50-day moving average price is $0.58 and its two-hundred day moving average price is $0.91. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.14. The stock has a market capitalization of $23.07 million, a P/E ratio of -0.26 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. As a group, equities research analysts expect that Jasper Therapeutics will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in shares of Jasper Therapeutics during the 1st quarter valued at about $46,000. Engineers Gate Manager LP acquired a new stake in Jasper Therapeutics during the second quarter valued at approximately $78,000. Panagora Asset Management Inc. bought a new stake in Jasper Therapeutics during the fourth quarter worth approximately $35,000. Voleon Capital Management LP acquired a new position in Jasper Therapeutics in the third quarter worth approximately $50,000. Finally, XTX Topco Ltd acquired a new position in Jasper Therapeutics in the second quarter worth approximately $152,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.